Zhejiang Cancer Hospital
🇨🇳China
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06393166
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
GMA-TulipTM, i-gelTM and the LMA-SupremeTM (LMA-S) Devices in Airway Management
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 276
- Registration Number
- NCT06383494
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06383533
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06364826
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06349044
- Locations
- 🇨🇳
Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06350162
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT06308939
- Locations
- 🇨🇳
zhejiangCH, Hangzhou, Zhejiang, China
Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06300489
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06292689
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 146
- Registration Number
- NCT06272214
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath